Novartis said recently that a review of the outcomes of a test of diabetics who had heart failure in which their left ventricle could no longer contract as it should indicates Entresto pills helped those diabetics better manage their blood sugar levels than enalapril.
Chemotherapy may save lives, but it can also cause patient hair loss – which is why pharmaceutical device maker Dignitana Inc. developed a special cap, recently FDA approved, to prevent this unpleasant side effect.
Positive results from a Phase 3 clinical trial recently prompted the European Commission to approve Besponsa, Pfizer Inc.’s new immunotherapy treatment for patients suffering from B-cell precursor acute lymphoblastic leukemia, the pharmaceutical said in a release.
The U.S. Food and Drug Administration said it is taking steps to promote wider access to lower-cost alternatives to prescription medication and facilitating efforts to bring more generic medications to the market.dd Teaser here
AbbVie said a subcommittee of the European Medicines Agency has recommended marketing authorization approval of hepatitis C drug Maviret, a step toward broadening the available treatments for patients with liver and kidney disease in approximately 30 European and Scandinavian countries.
Pfizer said its drug tafamidis, an investigational treatment for transthyretin cardiomyopathy (TTR-CM), a rare, fata disease linked to progressive heart failure, has been granted U.S. Food and Drug Administration (FDA) fast track designation.
Based on data from an international clinical trial, U.S. drugmaker Amgen has petitioned the Food and Drug Administration to allow use of Xgeva (denosumab) to prevent bone fractures among multiple myeloma patients.
In a move that could help open the U.S. market for biosimilars, a U.S. Food and Drug Administration subcommittee recently greenlighted Pfizer Inc.’s epoetin alfa compound, an emulation of two medicines designed to relieve anemia in patients who have cancer and kidney disease.
An amendment to an international Phase 3 clinical trial for prostate cancer drug Xtandi (enzalutamide) will cut the sample size by 120 subjects and provide results later this year, nearly two years ahead of schedule.
Horizon Pharma said in a release that a proposed generic version of its Pennsaid topical pain reliever has been sidelined in the U.S. by a court ruling upholding Horizon Pharma's patent infringement claim.